Literature DB >> 15087372

HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2).

Cristina Morerio1, Maura Acquila, Cristina Rosanda, Annamaria Rapella, Carlo Dufour, Franco Locatelli, Emanuela Maserati, Francesco Pasquali, Claudio Panarello.   

Abstract

PDGFRB, a transmembrane tyrosine kinase receptor for platelet-derived growth factor, is constitutively activated by gene fusion with different partners in myeloproliferative/myelodysplastic disorders with peculiar clinical characteristics. Six alternative partner genes have been described thus far. In this study, we report the molecular cloning of a novel translocation t(5;17)(q33;p11.2) in a case of juvenile myelomonocytic leukemia. The novel partner gene was identified as HCMOGT-1 using 5'-rapid amplification of cDNA ends; fluorescence in situ hybridization and reverse transcriptase-PCR analyses confirmed that the translocation resulted in PDGFRB/HCMOGT-1 fusion. We show that the breakpoint of PDGFRB occurred at the same site of all previously reported PDGFRB translocations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087372     DOI: 10.1158/0008-5472.can-03-4026

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.

Authors:  Yoshimitsu Shimomura; Hayato Maruoka; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2016-12-20       Impact factor: 2.490

2.  Conserved proline-directed phosphorylation regulates SR protein conformation and splicing function.

Authors:  Malik M Keshwani; Brandon E Aubol; Laurent Fattet; Chen-Ting Ma; Jinsong Qiu; Patricia A Jennings; Xiang-Dong Fu; Joseph A Adams
Journal:  Biochem J       Date:  2015-03-01       Impact factor: 3.857

3.  ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.

Authors:  Barbara Spitzer; Filemon S Dela Cruz; Glorymar D Ibanez Sanchez; Yanming Zhang; Wenbin Xiao; Ryma Benayed; Alina Markova; M Irene Rodriguez-Sanchez; Nancy Bouvier; Mikhail Roshal; Andrew L Kung; Neerav Shukla
Journal:  Blood Adv       Date:  2021-04-13

Review 4.  BCR-ABL-negative chronic myeloid leukemia.

Authors:  Sonja Burgstaller; Andreas Reiter; Nicholas C P Cross
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

Review 5.  PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Authors:  Mirela Andrei; Andrei Bandarchuk; Cherif Abdelmalek; Ajay Kundra; Vladimir Gotlieb; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2017-02-17

6.  A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report.

Authors:  Thayana Conceição Barbosa; Bruno Almeida Lopes; Caroline Barbieri Blunck; Marcela Braga Mansur; Adriana Vanessa Santini Deyl; Mariana Emerenciano; Maria S Pombo-de-Oliveira
Journal:  BMC Med Genomics       Date:  2018-12-18       Impact factor: 3.063

7.  Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins.

Authors:  Javier-Fernando Montero-Bullón; Óscar González-Velasco; María Isidoro-García; Jesus Lacal
Journal:  Orphanet J Rare Dis       Date:  2021-07-06       Impact factor: 4.123

8.  Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Nicola Aceto; Virginie Remy; Stephane Pinson; Claude Houdayer; Christine Arnoulet; Danielle Sainty; Mohamed Bentires-Alj; Sylviane Olschwang; Norbert Vey; Marie-Joëlle Mozziconacci; Daniel Birnbaum; Max Chaffanet
Journal:  BMC Cancer       Date:  2008-10-16       Impact factor: 4.430

Review 9.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

10.  Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides.

Authors:  Armando N Bastidas Torres; Davy Cats; Hailiang Mei; Karoly Szuhai; Rein Willemze; Maarten H Vermeer; Cornelis P Tensen
Journal:  Genes Chromosomes Cancer       Date:  2018-10-25       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.